{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-25-071413","form_type":"8-K","ticker":"KNSA","cik":"0001730430","company_name":"Kiniksa Pharmaceuticals International, plc","filed_at":"2025-07-29T23:59:59+00:00","discovered_at":"2026-05-14T18:02:44.828117+00:00","generated_at":"2026-05-17T23:45:27.454706+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"confidence":"high","headline":"Kiniksa Q2 ARCALYST revenue $156.8M (+52% YoY); raises 2025 guidance to $625-640M","bullets":["ARCALYST net product revenue $156.8M in Q2 2025, up 52% from $103.4M in Q2 2024 (excl. $5.2M license revenue).","2025 ARCALYST net revenue guidance raised to $625-640M from prior $590-605M, reflecting continued commercial execution.","Net income of $17.8M in Q2 2025 vs net loss of $3.9M in Q2 2024; cash and investments $307.8M, no debt.","KPL-387 Phase 2/3 trial in recurrent pericarditis recruiting; Phase 2 data expected in 2H 2026.","Approximately 15% of target 14,000 multiple-recurrence pericarditis patients currently on ARCALYST."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-25-071413","json":"https://secwatch.observer/filing/0001104659-25-071413.json","markdown":"https://secwatch.observer/filing/0001104659-25-071413.md","text":"https://secwatch.observer/filing/0001104659-25-071413.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1730430/000110465925071413/0001104659-25-071413-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1730430/000110465925071413/tm2521890d1_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-17T23:45:27.454706+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}